# Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

> **NCT06272487** · PHASE2 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 375 (actual)

## Conditions studied

- High Cardiovascular Risk
- Hypertension

## Interventions

- **DRUG:** Zilebesiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06272487
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-29
- **Primary completion:** 2025-06-19
- **Final completion:** 2025-12-01
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06272487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06272487, "Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06272487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*